Sign In
to Vote &
Create Storyboards.
 

Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma

New England Journal of Medicine - 31 May 2025 12:00
New England Journal of Medicine, Ahead of Print.
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard